Perspectives

Perspectives

Commentary and highlights from contributors and readers

The Present and Future Multiple Myeloma Landscape

The rapid pace of drug approvals in multiple myeloma (MM) shows no sign of abating. In the past two years, the U.S. Food and...

An Unabashed Rehash of the ASH Dash

(Or, How to Write an Abstract Guaranteed to be Selected for a Plenary Presentation at the Annual Meeting*) 6:15 a.m. (EST), August 4, 2015: My...

The Work-Life Spectrum

I wish we had a better term for the relationship between work and life, because, in my understanding, “work-life balance” suggests that in order...

A Day in the Life of a Hem/Onc APP

“What do you do in a typical day?” is a question I am often asked by everyone from nurses who aspire to further their...

A Few of My Favorite Things

It seems that my last “Editor’s Corner” column (“These Are a Few of My Least Favorite Things …,”) resonated with many of my fellow hematologists....

Equal Under the Law

What a remarkable couple of months it has been for the law, and for our patients. On Friday, June 26, the highest court in the...

The Cost of Treating Thrombosis

In their interesting debate (“Drawing First Blood: For Anticoagulation in Cancer-Associated Thrombosis, Is Less More?”) in the August issue of ASH Clinical News, David Garcia, MD, and...

Crossing the Generational Divide

“Millennials” or “Generation Y,” those of us born in the early 1980s who came of age around the turn of the century, don’t have...

Benign Hematology Isn’t So Benign

As a benign hematologist, I get a lot of questions about what I do and the kind of medicine I practice. When my parents want...

Managing the Oral Health Complications of Chemotherapy

What are the oral complications of cancer therapy that hematologists/oncologists should be aware of? The treatments for hematologic malignancies – chemotherapy, combinations of chemotherapy, or...
Advertisement

Current Issue

September 2018, Volume 4, Issue 11

View issue flipbook September 2018 Volume 4, Issue 11This issue features a look at research misconduct, a debate about whether chronic lymphocytic leukemia is curable, and...